These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36644129)

  • 1. High-dose dual therapy
    Zhou BG; Mei YZ; Zhang M; Jiang X; Li YY; Ding YB
    Therap Adv Gastroenterol; 2023; 16():17562848221147756. PubMed ID: 36644129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose dual therapy versus bismuth-containing quadruple therapy for the eradication of Helicobacter pylori: A systematic review and meta-analysis.
    Wang H; Kong QZ; Li YY; Yang XY; Zuo XL
    J Dig Dis; 2024 Mar; 25(3):163-175. PubMed ID: 38577962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of
    Zhang C; Zhang J; Cheng YJ
    Saudi J Gastroenterol; 2023; 29(2):88-94. PubMed ID: 36960527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
    Zhou BG; Jiang X; Ding YB; She Q; Li YY
    Helicobacter; 2024; 29(1):e13040. PubMed ID: 37983865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of high-dose esomeprazole and amoxicillin dual therapy
    Mei H; Guo Y; Zhao JT; Yang J; Sun WJ; Zhang DK; He P; Shi G; Su NY; Han R; Lan CH
    Therap Adv Gastroenterol; 2022; 15():17562848221142925. PubMed ID: 36600686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: A systematic review and meta-analysis.
    Yang X; Wang JX; Han SX; Gao CP
    Medicine (Baltimore); 2019 Feb; 98(7):e14396. PubMed ID: 30762742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of supplementing with
    Chen Y; Teng T; Su Y; Chen WZ
    Front Med (Lausanne); 2024; 11():1344702. PubMed ID: 38695028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety of high-dose dual therapy, bismuth-based quadruple therapy and non-bismuth quadruple therapies for Helicobacter pylori infection: a network meta-analysis.
    Xu H; Wang W; Ma X; Feng R; Su Y; Cheng L; Yang Y; Zhang D
    Eur J Gastroenterol Hepatol; 2021 Jun; 33(6):775-786. PubMed ID: 32639419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Efficacy and Safety of Regimens for Helicobacter pylori Eradication Treatment in China: A Systemic Review and Network Meta-Analysis.
    Li J; Shi H; Zhou F; Xie L; Lin R
    J Clin Gastroenterol; 2024 Jan; 58(1):12-23. PubMed ID: 38084866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High dose PPI-amoxicillin dual therapy for the treatment of
    Zhu YJ; Zhang Y; Wang TY; Zhao JT; Zhao Z; Zhu JR; Lan CH
    Therap Adv Gastroenterol; 2020; 13():1756284820937115. PubMed ID: 33110448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial.
    Bi H; Chen X; Chen Y; Zhao X; Wang S; Wang J; Lyu T; Han S; Lin T; Li M; Yuan D; Liu J; Shi Y
    Chin Med J (Engl); 2022 Jul; 135(14):1707-1715. PubMed ID: 36193978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimum duration of regimens for Helicobacter pylori eradication.
    Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic changes in the gut microbiota after bismuth quadruple therapy and high-dose dual therapy for Helicobacter pylori eradication.
    Chen J; Zhang Y; Min H; Zhi J; Ma S; Dong H; Yan J; Chi X; Zhang X; Yang Y
    Helicobacter; 2024; 29(2):e13077. PubMed ID: 38682268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: A single-center, prospective, open-label, randomized-controlled trial.
    Shao QQ; Yu XC; Yu M; Ma J; Zhao JB; Yuan L; Qi YB; Hu RB; Wei PR; Xiao W; Lan L; Jia BL; Zhang LZ; Ding SZ
    Helicobacter; 2022 Apr; 27(2):e12876. PubMed ID: 35150597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Helicobacter pylori eradication with high-dose proton pump inhibitor-amoxicillin dual therapy: A systematic review and meta-analysis.
    Yeh JA; Huang HK; Chou AL; Lin HJ; Feng CL; Kuo CJ; Lai CH
    Int J Antimicrob Agents; 2024 Jun; 63(6):107159. PubMed ID: 38554984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-Dose Dual Therapy Versus Bismuth-Containing Quadruple Therapy for the Treatment of Helicobacter pylori Infection: A Systematic Review with Meta-Analysis.
    Yin Z; Li J; Huang W; Lei X; Xu D; Xu G; Li H; Zhang J
    Turk J Gastroenterol; 2022 Jun; 33(6):454-462. PubMed ID: 35786612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
    Tian XL; Suo BJ; Zhang H; Lu HP; Li CL; Zhang YX; Ren XL; Yao XY; Zhou LY; Song ZQ
    Helicobacter; 2023 Feb; 28(1):e12935. PubMed ID: 36374159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose dual therapy
    Zhao Z; Zou PY; Su NY; Guo Y; Wang XW; Zhao JT; Mei H; Shi Q; Wang B; Chen DF; Lan CH
    Therap Adv Gastroenterol; 2022; 15():17562848221145566. PubMed ID: 36600682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empirical
    Li M; Wang X; Meng W; Dai Y; Wang W
    Therap Adv Gastroenterol; 2023; 16():17562848231196357. PubMed ID: 37667805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial.
    Kim YI; Lee JY; Kim CG; Park B; Park JY; Choi IJ
    BMC Gastroenterol; 2021 Mar; 21(1):95. PubMed ID: 33653284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.